Genmab A/S reported that worldwide 2025 net trade sales of the cancer medicine DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on all worldwide net sales of both the intravenous and subcutaneous products under its exclusive license agreement with Johnson & Johnson. The filing also reiterates that Genmab is a biotechnology company focused on antibody-based medicines, with multiple approved therapies and a late-stage clinical pipeline.
Genmab A/S reported topline Phase 3 results from the EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). In 483 patients ineligible for high-dose chemotherapy and transplant, subcutaneous epcoritamab monotherapy improved progression-free survival with a hazard ratio of 0.74 (95% CI 0.60–0.92) versus chemotherapy. Complete response rate, duration of response and time to next treatment also improved with epcoritamab.
Overall survival showed a hazard ratio of 0.96 (95% CI 0.77–1.20) and did not reach statistical significance. The safety profile appeared consistent with known risks, including cytokine release syndrome, neurologic events, infections and low blood counts as highlighted in the EPKINLY prescribing information. Genmab and AbbVie plan to discuss these results with global regulators and expect additional Phase 3 data for fixed-duration epcoritamab regimens in DLBCL during 2026.
Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.